+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita



Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita



Journal Of The American Academy Of Dermatology. 36(2 Part 2): 331-335



Epidermolysis bullosa acquisita is an uncommon autoimmune bullous disease of the skin and mucous membranes. It is chronic, disabling, and difficult to treat. We describe a case of severe epidermolysis bullosa acquisita of 7 years' duration that had been treated with azathioprine, corticosteroids, chlorambucil, plasma exchanges, cyclophosphamide, cyclosporine, and colchicine without any lasting effect. Seven cycles of treatment were administered with immunoglobulin given intravenously at a low dose, 40 mg/kg body weight daily for 5 days. The patient was free of disease for 10 months after the initiation of therapy. We suggest that low-dose regimens of immunoglobulins may be as effective in this disease as the high-dose regimens suggested in the literature, and at much lower cost.

(PDF emailed within 0-6 h: $19.90)

Accession: 008910049

Download citation: RISBibTeXText

PMID: 9039213

DOI: 10.1016/s0190-9622(97)80411-2



Related references

Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. Journal of Dermatological Treatment (): 1-5, 2016

Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up. Journal of the European Academy of Dermatology and Venereology 26(9): 1074-1083, 2012

Results of intravenous immunoglobulin therapy in ocular involvement in epidermolysis bullosa acquisita. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 1388, 2003

Intravenous immunoglobulin therapy in patients with epidermolysis bullosa acquisita refractory to conventional therapy. Journal of Investigative Dermatology 121(1): 1232, July, 2003

Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. Journal of the European Academy of Dermatology and Venereology 16(1): 77-80, 2002

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita. Clinical Immunology 129(3): 518-519, 2008

Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin. Clinical and Experimental Dermatology 31(1): 71-73, 2005

Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. British Journal of Dermatology 132(5): 824-826, 1995

Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. British Journal of Dermatology 157(2): 417-419, 2007

Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. Journal of Dermatology 39(5): 477-479, 2012

Heavy and light chain isotypes of immunoglobulin in epidermolysis bullosa acquisita. Journal of Investigative Dermatology 95(3): 317-319, 1990

Absence of platelet aggregation activity in blister fluids from epidermolysis bullosa dystrophica and epidermolysis bullosa acquisita. Journal of Dermatological Science 1(6): 467-468, 1990

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. Journal of the American Academy of Dermatology 31(5 Pt 1): 827-828, 1994

Clinicopathological case 1: mucous membrane pemphigoid, epidermolysis bullosa acquisita and linear immunoglobulin A disease. Clinical and Experimental Dermatology 28(4): 461-462, 2003

Epidermolysis bullosa acquisita in childhood. Differentiation from hereditary epidermolysis bullosa. Archives of Dermatology 125(7): 944-949, 1989